Absence of hMLH1 or hMSH2 Expression as a Stage-Dependent Prognostic Factor in Sporadic Colorectal Cancers

By Park Ji  

Annals of Surgical Oncology, Vol. 17, Iss. 11, 2010-11 ,pp. : 2839-2846

Springer Publishing Company

Access to resources Recommend Favorite

Randomized Study Comparing Carboplatin/Cyclophosphamide and Cisplatin/Cyclophosphamide as First-Line Treatment in Patients with Stage III/IV Epithelial Ovarian Cancer and Small Volume Disease

By Meerpohl H.G.   Sauerbrei W.   Kuhnle H.   Schumacher M.   Pfleiderer A.   German Ovarian Cancer Study Group GOCA  

Gynecologic Oncology, Vol. 66, Iss. 1, 1997-07 ,pp. : 75-84

Elsevier

Access to resources Recommend Favorite

Paclitaxel/carboplatin with or without sorafenib in the first‐line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute

By  

Cancer Medicine, Vol. 4, Iss. 5, 2015-05 ,pp. : 673-681

John Wiley & Sons Inc

Access to resources Recommend Favorite

Germline Mutations of the hMLH1 and hMSH2 Mismatch Repair Genes in Belgian Hereditary Nonpolyposis Colon Cancer (HNPCC) Patients

By Spaepen M.   Vankeirsbilck B.   Opstal S.   Tejpar S.   Cutsem E.   Geboes K.   Legius E.   Matthijs G.  

Familial Cancer, Vol. 5, Iss. 2, 2006-06 ,pp. : 179-189

Springer Publishing Company

Access to resources Recommend Favorite

Meat and Fish Consumption, APC Gene Mutations and hMLH1 Expression in Colon and Rectal Cancer: a Prospective Cohort Study (The Netherlands)

By Lüchtenborg Margreet  

Cancer Causes and Control, Vol. 16, Iss. 9, 2005-11 ,pp. : 1041-1054

Springer Publishing Company

Access to resources Recommend Favorite